SCHEMBL1701003

SCHEMBL1701003

CCCCCN(O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 6/20 0.47
KDM4C Q9H3R0 4/20 0.47
KDM5C P41229 1/20 0.47
KDM5B Q9UGL1 1/20 0.47
PHF8 Q9UPP1 3/20 0.46
AKR1B1 P15121 1/20 0.44
GPR84 Q9NQS5 7/20 0.42
PPARG P37231 6/20 0.42
PPARD Q03181 6/20 0.42
PPARA Q07869 6/20 0.42
HDAC11 Q96DB2 5/20 0.42
TSHR P16473 4/20 0.42
ALDH1A1 P00352 2/20 0.42
TLR2 O60603 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
FABP4 P15090 2/20 0.42
PTPN1 P18031 2/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6253808 0.98 KDM5A (0.49) KDM5AKDM4CKDM5CKDM5BPHF8
SCHEMBL11528780 0.98 KDM5A (0.49) KDM5AKDM4CKDM5CKDM5BPHF8
SCHEMBL6249750 0.98 KDM5A (0.49) KDM5AKDM4CKDM5CKDM5BPHF8
SCHEMBL6253897 0.98 KDM5A (0.49) KDM5AKDM4CKDM5CKDM5BPHF8
SCHEMBL6253780 0.98 KDM5A (0.49) KDM5AKDM4CKDM5CKDM5BPHF8
SCHEMBL851935 0.92
SCHEMBL629319 0.81
SCHEMBL10835091 0.80 KDM5A (0.43) KDM5AKDM4CKDM5CKDM5BPHF8
SCHEMBL1694839 0.78 AKR1B1 (0.42) KDM5AKDM4CKDM5CKDM5BPHF8
SCHEMBL7825058 0.78 KDM5A (0.42) KDM5AKDM4CKDM5CKDM5BPHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4359006-A1 ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS Entrada Therapeutics, Inc. (US) 2024-05-01 EP disclosed
EP-4337263-A1 COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY Entrada Therapeutics, Inc. (US) 2024-03-20 EP disclosed
EP-4337264-A1 COMPOSITIONS AND METHODS FOR MODULATING TISSUE DISTRIBUTION OF INTRACELLULAR THERAPEUTICS Entrada Therapeutics, Inc. (US) 2024-03-20 EP disclosed
EP-4337261-A2 COMPOSITIONS AND METHODS FOR MODULATING MRNA SPLICING Entrada Therapeutics, Inc. (US) 2024-03-20 EP disclosed
WO-2022271818-A1 ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS ENTRADA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed
WO-2021127650-A1 COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS ENTRADA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2011163121-A1 MULTIFUNCTIONAL COPOLYMERS FOR NUCLEIC ACID DELIVERY ALNYLAM PHARMACEUTICALS, INC. (US) 2011-12-29 WO disclosed
EP-2081949-A2 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE Dharmacon, Inc. (US) 2009-07-29 EP disclosed
WO-2009015071-A1 SCREENING OF MICRO-RNA CLUSTER INHIBITOR POOLS DHARMACON, INC. (US) 2009-01-29 WO disclosed
WO-2008036841-A2 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC. (US) 2008-03-27 WO disclosed
WO-2005047234-A1 METHOD FOR PRODUCING CARBAMATE GROUP-CONTAINING (METH)ACRYLIC ESTERS Röhm GmbH & Co. KG (DE) 2005-05-26 WO disclosed
US-5395911-A Basic catalyst, solvent; coatings DAINIPPON INK AND CHEMICALS, INC. (JP) 1995-03-07 US disclosed